KBC Group NV Sells 56,441 Shares of LivaNova PLC (NASDAQ:LIVN)

KBC Group NV decreased its position in LivaNova PLC (NASDAQ:LIVN - Free Report) by 56.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 43,487 shares of the company's stock after selling 56,441 shares during the quarter. KBC Group NV owned about 0.08% of LivaNova worth $1,708,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in LIVN. UMB Bank n.a. grew its holdings in shares of LivaNova by 340.5% during the 1st quarter. UMB Bank n.a. now owns 837 shares of the company's stock valued at $33,000 after purchasing an additional 647 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after acquiring an additional 219 shares during the last quarter. Sterling Capital Management LLC grew its stake in shares of LivaNova by 800.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock worth $75,000 after purchasing an additional 1,441 shares during the last quarter. Vestcor Inc bought a new stake in shares of LivaNova in the fourth quarter worth $204,000. Finally, Central Pacific Bank Trust Division grew its stake in shares of LivaNova by 7.0% in the first quarter. Central Pacific Bank Trust Division now owns 4,407 shares of the company's stock worth $173,000 after purchasing an additional 290 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

LivaNova Stock Down 1.2%

NASDAQ:LIVN traded down $0.55 on Monday, hitting $45.58. The stock had a trading volume of 502,649 shares, compared to its average volume of 637,772. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $57.35. The business's fifty day moving average is $43.80 and its 200 day moving average is $43.26. The company has a quick ratio of 1.37, a current ratio of 1.58 and a debt-to-equity ratio of 0.53. The company has a market cap of $2.49 billion, a PE ratio of -11.14 and a beta of 0.90.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Needham & Company LLC reiterated a "buy" rating and issued a $64.00 target price on shares of LivaNova in a report on Tuesday, May 13th. Wolfe Research raised shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 price objective on the stock in a research note on Tuesday, May 20th. Wall Street Zen lowered shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. Robert W. Baird upped their price target on shares of LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Finally, Barclays cut their price target on shares of LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $59.29.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.